FDA Grants Nivolumab Priority Review in Nonsquamous NSCLC

Wednesday, September 2, 2015

Source: OncLive

Nivolumab (Opdivo) has received an FDA priority review designation for patients with previously treated nonsquamous non­–small cell lung cancer (NSCLC), according to the developer of the PD-1 inhibitor, Bristol-Myers Squibb (BMS). Under the expedited process, the FDA’s decision deadline is January 2, 2016.

View All News »